% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • strongsell12 strongsell12 Apr 30, 2013 10:44 AM Flag

    sell all AFFY all in SVNT you will get back everything

    Sobi and Savient Pharmaceuticals Inc Announce Co-Promotion Agreement for Kineret in US
    Tuesday, 19 Feb 2013 08:30am EST
    Sobi and Savient Pharmaceuticals Inc announced that they have entered into an agreement for the co-promotion of Kineret (anakinra) in the U.S. Kineret, a recombinant IL-1 receptor antagonist, is a treatment for rheumatoid arthritis (RA) and indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active RA in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs). Kineret is also indicated in the U.S. for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Under the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the U.S. Savient will market and promote Kineret beginning April 1, 2013. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities. About Swedish Orphan Biovitrum AB (Sobi) Sobi is an international specialty healthcare company dedicated to rare diseases.
    Latest Developments for Savient Pharmaceuticals IncSavient Pharmaceuticals Inc Announces CEO Appointment
    Savient Pharmaceuticals Inc Announces That New Analysis of Phase III Trials Shows Gout Patients with Chronic Kidney Disease at Any Stage Responded to KRYSTEXXA
    Savient Pharmaceuticals Inc Appoints David Y. Norton Interim Chief Executive Officer
    Latest Key Developments in BiotechnologyDynavax Technologies Corp Announces Management Changes
    Intercept Pharmaceuticals Inc Announces Additional Results Of Global Primary Biliary Cirrhosis Study Group Analysis

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.095+0.0040(+4.40%)Oct 9 3:17 PMEDT